|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1982-3-22
|
|
pubmed:abstractText |
A four-drug combination of intermittent high-dose cyclophosphamide with 5-fluorouracil, hexamethylmelamine, and prednisone was given to 19 patients with advanced breast cancer. Objective response was documented in 7 of 18 evaluable patients. The median duration of response was 99 days. Response was observed in 6/7 patients without visceral disease and 1/11 patients with visceral disease. Toxicity was acceptable and no life-threatening toxicity was observed. Three patients have received the four-drug combination for more than 1 year without serious side effects. This regimen may serve as an alternative treatment for patients without visceral metastasis who have failed to respond to other combination chemotherapy regimens.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0190-1206
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
4
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
377-80
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:6797746-Adenocarcinoma,
pubmed-meshheading:6797746-Adult,
pubmed-meshheading:6797746-Aged,
pubmed-meshheading:6797746-Altretamine,
pubmed-meshheading:6797746-Antineoplastic Agents,
pubmed-meshheading:6797746-Breast Neoplasms,
pubmed-meshheading:6797746-Cyclophosphamide,
pubmed-meshheading:6797746-Dose-Response Relationship, Drug,
pubmed-meshheading:6797746-Drug Evaluation,
pubmed-meshheading:6797746-Drug Therapy, Combination,
pubmed-meshheading:6797746-Female,
pubmed-meshheading:6797746-Fluorouracil,
pubmed-meshheading:6797746-Humans,
pubmed-meshheading:6797746-Leukopenia,
pubmed-meshheading:6797746-Middle Aged,
pubmed-meshheading:6797746-Nausea,
pubmed-meshheading:6797746-Prednisone
|
|
pubmed:year |
1981
|
|
pubmed:articleTitle |
Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.
|
